专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050181055A1 Pharmaceutical compositions of quinapril 审中-公开
标题翻译：喹那普利的药物组合物
公开(公告)号：US20050181055A1
公开(公告)日：2005-08-18
申请号：US10962100
申请日：2004-10-08
申请人： Rajeev Mathur , Sameer Manan , Sanjeev Sethi
发明人： Rajeev Mathur , Sameer Manan , Sanjeev Sethi
IPC分类号： A61K9/20 , A61K31/401 , A61K9/14 , A61K33/10
CPC分类号： A61K9/2009 , A61K9/2077 , A61K31/401
摘要： The present invention relates to pharmaceutical compositions of quinapril and processes for their preparation. One pharmaceutical composition includes a therapeutically effective amount of quinapril or an acid addition salt thereof and between about 15% w/w to about 40% w/w of an alkaline substance.
摘要翻译：本发明涉及喹那普仑的药物组合物及其制备方法。一种药物组合物包括治疗有效量的喹那普利或其酸加成盐和约15％w / w至约40％w / w的碱性物质。

2. 发明申请

US20070185194A1 Stable oral compositions of azithromycin monohydrate 审中-公开
标题翻译：稳定的阿奇霉素一水合物的口服组合物
公开(公告)号：US20070185194A1
公开(公告)日：2007-08-09
申请号：US10561827
申请日：2004-07-01
申请人： Kamal Mehta , Rajeev Mathur , Sujata Paul , Sanjeev Sethi , Rajiv Malik
发明人： Kamal Mehta , Rajeev Mathur , Sujata Paul , Sanjeev Sethi , Rajiv Malik
IPC分类号： A61K31/35
CPC分类号： A61K9/0095 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K31/70
摘要： The present invention relates to stable oral compositions of azithromycin monohydrate with reduced bitterness, processes for making these compositions, and methods of using these compositions for the treatment of microbial infections. The stable oral compositions of azithromycin include an azithromycin premix, at least one pharmaceutically accepted excipient, and, optionally, at least one taste-masking agent. The azithromycin premix includes azithromycin monohydrate and at least one additive.
摘要翻译：本发明涉及具有降低的苦味的阿奇霉素一水合物的稳定口服组合物，以及制备这些组合物的方法，以及使用这些组合物治疗微生物感染的方法。阿奇霉素的稳定的口服组合物包括阿奇霉素预混物，至少一种药学上可接受的赋形剂和任选的至少一种掩味剂。阿奇霉素预混物包括阿奇霉素一水合物和至少一种添加剂。

3. 发明申请

US20060159751A1 Controlled release pharmaceutical compositions of carbidopa and levodopa 审中-公开
标题翻译：卡比多巴和左旋多巴的控释药物组合物
公开(公告)号：US20060159751A1
公开(公告)日：2006-07-20
申请号：US10510468
申请日：2003-04-11
申请人： Mona Gogia , Rajeev Mathur , Sanjeev Sethi
发明人： Mona Gogia , Rajeev Mathur , Sanjeev Sethi
IPC分类号： A61K31/198 , A61K31/717 , A61K9/22
CPC分类号： A61K31/195 , A61K9/2054
摘要： The present invention relates to controlled release pharmaceutical compositions of carbidopa and levodopa that include a combination of different molecular weight cellulose ethers and in particular, hydroxypropyl cellulose ether.
摘要翻译：本发明涉及卡比多巴和左旋多巴的控释药物组合物，其包括不同分子量的纤维素醚，特别是羟丙基纤维素醚的组合。

4. 发明申请

US20050202083A1 Storage stable tablets of fosinopril sodium 审中-公开
标题翻译：储存稳定的福辛普利钠片
公开(公告)号：US20050202083A1
公开(公告)日：2005-09-15
申请号：US10523419
申请日：2003-08-01
申请人： Pananchukunnath Kumar , Rajeev Mathur , Sanjeev Sethi , Rajiv Malik
发明人： Pananchukunnath Kumar , Rajeev Mathur , Sanjeev Sethi , Rajiv Malik
IPC分类号： A61K9/20 , A61K31/675 , A61K45/06 , A61P9/04 , A61P9/12 , A61K31/66
CPC分类号： A61K45/06 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K31/675 , A61K2300/00
摘要： The technical field of the present invention relates to the selection of lubricants to provide a storage stable tablet of fosinopril, alone or in combination with a diuretic, as well as processes of preparation of the stable tablets. In particular, the lubricants are a combination of colloidal silicon dioxide and talc.
摘要翻译：本发明的技术领域涉及润滑剂的选择，以提供单独或与利尿剂组合的福辛普利的储存稳定片剂，以及制备稳定片剂的方法。特别地，润滑剂是胶体二氧化硅和滑石的组合。

5. 发明申请

US20080023856A1 Halide Reduction in Dihydrocarbylmagnesium Mixtures 有权
标题翻译：二烃基镁混合物中的卤化物还原
公开(公告)号：US20080023856A1
公开(公告)日：2008-01-31
申请号：US11718380
申请日：2004-11-12
申请人： Milind Pradhan , Chi Cheng , Rajeev Mathur , Richard Holub , Donald Imhoff
发明人： Milind Pradhan , Chi Cheng , Rajeev Mathur , Richard Holub , Donald Imhoff
IPC分类号： C07F3/02
CPC分类号： C07F3/02
摘要： This invention provides a process for reducing the amount of soluble halide in a solution comprising a liquid organic medium, at least one viscosity reducing agent, at least one dihydrocarbylmagnesium compound, and an initial amount of soluble halide. The process comprises mixing at least one alkali metal with the solution at a mole ratio of alkali metal to magnesium of less than about 1:2.5, thereby forming precipitated soluble halides. Also provided by this invention is a process for reducing the amount of soluble halide in a slurry comprising a liquid organic medium, at least one viscosity reducing agent, at least one dihydrocarbylmagnesium compound, solids from the formation of said dihydrocarbylmagnesium compound, and an initial amount of soluble halide. This process comprises mixing at least one alkali metal with the slurry at a mole ratio of alkali metal to magnesium of less than about 1:1.25, thereby forming precipitated soluble halides.
摘要翻译：本发明提供一种减少包含液体有机介质，至少一种降粘剂，至少一种二烃基镁化合物和初始量的可溶性卤化物的溶液中的可溶性卤化物的量的方法。该方法包括将碱金属与镁的摩尔比以小于约1:2.5的比例混合至少一种碱金属与溶液，由此形成沉淀的可溶性卤化物。本发明还提供一种减少包含液体有机介质，至少一种粘度降低剂，至少一种二烃基镁化合物，形成所述二烃基镁化合物的固体和初始量的浆料中的可溶性卤化物的量的方法的可溶性卤化物。该方法包括将碱金属与镁的摩尔比以小于约1：1.25的比例混合至少一种碱金属，从而形成沉淀的可溶性卤化物。

6. 发明申请

US20070197831A1 Process for producing tetrakis(faryl)borate-salts 审中-公开
标题翻译：生产四（faryl）硼酸盐的方法
公开(公告)号：US20070197831A1
公开(公告)日：2007-08-23
申请号：US10589413
申请日：2004-04-01
申请人： John Lee , Rajeev Mathur
发明人： John Lee , Rajeev Mathur
IPC分类号： C07F5/02
CPC分类号： C07F5/027
摘要： This invention provides a process for producing a protic ammonium tetrakis(Faryl)borate. The process comprises mixing together (a) at least one alkali metal tetrakis(Faryl)borate, at least one magnesium tetrakis(Faryl)borate, at least one halo-magnesium tetrakis(Faryl)borate, or a mixture of two or more of the foregoing, (b) at least one amine, and (c) one or more liquid dihydrocarbyl ethers, one or more liquid hydrocarbons, one or more liquid halogenated hydrocarbons, or a mixture of two or more of the foregoing, to form a solution or slurry in a liquid organic medium. At least one protic acid is mixed together with at least a portion of the solution or slurry formed in i), such that a protic ammonium tetrakis(Faryl)borate is formed. The amine has the formula R3N, in which each R is independently a hydrocarbyl group containing up to about thirty carbon atoms. Each of the Faryl groups is a fluorine-containing aryl group that has bonded directly to an aromatic ring at least two fluorine atoms, or at least two perfluorohydrocarbyl groups, or at least one fluorine atom and at least one perfluorohydrocarbyl group.
摘要翻译：本发明提供了一种生产四氨基四氢（P）芳基）质子铵的方法。所述方法包括将（a）至少一种碱金属四（非 - 氟）芳基）硼酸盐，至少一种四（四丁基）芳基硼酸镁，至少一种卤代 - 或四种（F）芳基）硼酸镁，或上述两种或多种的混合物，（b）至少一种胺，和（c）一种或多种液体二烃基醚，一种或多种液体烃，一种或多种液体卤代烃，或两种或更多种前述物质的混合物，以在液体有机介质中形成溶液或浆液。将至少一种质子酸与i）中形成的溶液或浆料的至少一部分混合在一起，从而形成四氨基四（四氢呋喃）四磷酸铵。胺具有式R 3 N，其中每个R独立地是含有至多约30个碳原子的烃基。每一个芳基都是含氟芳基直接与芳环键合至少两个氟原子，或至少两个全氟烃基，或至少一个氟原子，至少有一个氟原子一个全氟烃基。

7. 发明申请

US20060233875A1 Taste masked sumatriptan tablets and processes for their preparation 审中-公开
标题翻译：口味掩蔽的舒马曲坦片剂及其制备方法
公开(公告)号：US20060233875A1
公开(公告)日：2006-10-19
申请号：US10521402
申请日：2003-07-17
申请人： Rajeev Mathur , T. Kumar , Sunilendu Roy , Rajiv Malik
发明人： Rajeev Mathur , T. Kumar , Sunilendu Roy , Rajiv Malik
IPC分类号： A61K9/20 , B27N3/00
CPC分类号： A61K9/282 , A61K9/1623 , A61K9/2077 , A61K9/2081 , A61K9/5078 , A61K31/4045
摘要： The technical field of the present invention relates to uncoated, taste masked sumatriptan tablets for oral administration and processes for their preparation. It also relates to wax polished sumatriptan tablets and processes for their preparation.
摘要翻译：本发明的技术领域涉及用于口服给药的无涂层，掩味的舒马曲坦片剂及其制备方法。它还涉及蜡抛光舒马普坦片及其制备方法。

8. 发明申请

US20050202081A1 Stable pharmaceutical compositions comprising ace inhibitor(s) 审中-公开
标题翻译：包含ace抑制剂的稳定的药物组合物
公开(公告)号：US20050202081A1
公开(公告)日：2005-09-15
申请号：US10501450
申请日：2003-01-14
申请人： Deepak Bahl , Ravi Kochhar , Puneet Sharma , Vishnubhotla Nagaprasad , Rajeev Mathur , Kamal Mehta
发明人： Deepak Bahl , Ravi Kochhar , Puneet Sharma , Vishnubhotla Nagaprasad , Rajeev Mathur , Kamal Mehta
IPC分类号： A61K9/20 , A61K9/24 , A61K31/401 , A61K38/55 , A61K9/64
CPC分类号： A61K38/556 , A61K9/2086 , A61K9/209 , A61K31/401
摘要： The invention provides stable pharmaceutical compositions comprising ACE inhibitor(s) and other pharmaceutically active substances which are susceptible to degradation, as well as processes for the preparation thereof, and methods of treatment involving administration of such compositions.
摘要翻译：本发明提供了稳定的药物组合物，其包含ACE抑制剂和易于降解的其它药物活性物质，以及其制备方法，以及涉及施用该组合物的治疗方法。

9. 发明申请

US20070202159A1 PHARMACEUTICAL COMPOSITION COMPRISING STABILIZED STATIN PARTICLES 审中-公开
标题翻译：包含稳定的苯菌胺颗粒的药物组合物
公开(公告)号：US20070202159A1
公开(公告)日：2007-08-30
申请号：US11670107
申请日：2007-02-01
申请人： Rajeev Mathur , Romi Singh , Swati Aggarwal
发明人： Rajeev Mathur , Romi Singh , Swati Aggarwal
IPC分类号： A61K9/48 , A61K9/20 , A61K9/14
CPC分类号： A61K31/40 , A61K9/2018 , A61K9/288
摘要： The present invention relates to stabilized statin particles and process for preparation thereof.
摘要翻译：本发明涉及稳定的他汀类药物颗粒及其制备方法。

10. 发明申请

US20060189565A1 Pharmaceutical compositions of ganciclovir 审中-公开
标题翻译：更昔洛韦的药物组合物
公开(公告)号：US20060189565A1
公开(公告)日：2006-08-24
申请号：US10532024
申请日：2003-10-22
申请人： Rajeev Mathur , Pananchukunnath Kumar , Sunilendu Roy , Rajiv Malik
发明人： Rajeev Mathur , Pananchukunnath Kumar , Sunilendu Roy , Rajiv Malik
IPC分类号： A61K31/7072
CPC分类号： A61K9/2077 , A61K31/522
摘要： The technical field of the invention relates to pharmaceutical compositions of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir) that are stable and contain more than 1% water content. One pharmaceutical composition includes ganciclovir having more than about 1% water content, and one or more pharmaceutically acceptable excipients. The ganciclovir retains at least about 97% of its initial purity after one month, at least about 96% of its initial purity after two months, and at least about 95% of its initial purity after three months when stored at 40° C. and 75% RH. In particular, the water content may be between about 2% and about 6%.
摘要翻译：本发明的技术领域涉及稳定且含有1％以上含水量的9-（1,3-二羟基-2-丙氧基甲基）鸟嘌呤（更昔洛韦）的药物组合物。一种药物组合物包括具有超过约1％水含量的更昔洛韦和一种或多种药学上可接受的赋形剂。更昔洛韦保存至少约97％的初始纯度一个月后，至少约96％的初始纯度两个月后，至少约95％的初始纯度三个月后储存在40°C和 75％RH。特别地，水含量可以在约2％至约6％之间。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式